$IMVT

Immunovant, Inc.

CIK:0001764013|SEC Filings

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development	$ 142,631	$ 101,200
General and administrative	17,692	26,024
Total operating expenses	160,323	127,224
Interest income, net	(7,095)	(6,337)
Other income, net	(4)	(1,187)
Loss before provision for income taxes	(153,224)	(119,700)
Provision for income taxes	0	913
Net loss	$ (153,224)	$ (120,613)
Net loss per common share - basic (in dollars per share)	$ (0.75)	$ (0.71)
Net loss per common share - diluted (in dollars per share)	$ (0.75)	$ (0.71)
Weighted-average common shares outstanding – basic (in shares)	205,545,373	170,872,994
Weighted-average common shares outstanding – diluted (in shares)	205,545,373	170,872,994

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net loss	$ (153,224)	$ (120,613)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	13,774	18,510
Depreciation on property and equipment	92	107
Non-cash lease expense	27	24
Changes in operating assets and liabilities:
Accounts receivable	436	129
Prepaid expenses and other current assets	(4,953)	498
Other assets	6,763	(1,361)
Accounts payable	2,597	(9,401)
Accrued expenses and other current liabilities	10,083	(5,304)
Net cash used in operating activities	(124,405)	(117,411)
Cash flows from financing activities
Proceeds from stock options exercised	20,097	2,918
Net cash provided by financing activities	20,097	2,918
Effect of exchange rate changes on cash and cash equivalents	(4)	(566)
Net change in cash and cash equivalents	(104,312)	(115,059)
Cash and cash equivalents – beginning of period	902,110	713,971
Cash and cash equivalents – end of period	797,798	598,912
Non-cash financing activity
Issuance of common stock upon stock option exercises, cash not yet received	$ 2,154	$ 0

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Mar. 31, 2026
Current assets:
Cash and cash equivalents	$ 797,798	$ 902,110
Accounts receivable	697	1,133
Prepaid expenses and other current assets	52,683	45,576
Total current assets	851,178	948,819
Property and equipment, net	351	443
Other assets	961	7,752
Total assets	852,490	957,014
Current liabilities:
Accounts payable	10,138	7,541
Accrued expenses and other current liabilities	106,964	96,881
Total current liabilities	117,102	104,422
Total liabilities	117,102	104,422
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 206,264,878 shares issued and outstanding at June 30, 2026 and 500,000,000 shares authorized, 203,940,353 shares issued and outstanding at March 31, 2026	20	20
Additional paid-in capital	2,632,996	2,596,971
Accumulated other comprehensive income	725	730
Accumulated deficit	(1,898,353)	(1,745,129)
Total stockholders’ equity	735,388	852,592
Total liabilities and stockholders’ equity	852,490	957,014
Series A preferred stock
Stockholders’ equity:
Preferred stock	0	0
Preferred Stock
Stockholders’ equity:
Preferred stock	$ 0	$ 0